AED 20m gift puts Hamdan Bin Rashid Cancer Hospital on 2026 commissioning clock

Al Jalila Foundation secured a AED 20 million contribution from the Easa Saleh Al Gurg Charity Foundation to fund core engineering systems at Hamdan Bin Rashid Cancer Hospital before its planned 2026 opening.

For healthcare executives, the practical issue is commissioning risk: fire response, evacuation and emergency power systems must work before oncology volumes move into Dubai Health's new public-sector cancer hub.

What the AED 20 million funds

The agreement was signed at Al Jalila Foundation by Dr Amer Al Zarooni, Chief Executive Officer of Al Jalila Foundation, and Easa Al Gurg, Group CEO of Al Gurg Group, according to Khaleej Times on 19 June 2026. Dr Raja Easa Al Gurg, Chairperson of Easa Saleh Al Gurg Charity Foundation, and Dr Amer Sharif, CEO of Dubai Health, attended the signing.

Scientechnic and Al Gurg Automation & Controls (AGAC), both part of Al Gurg Group, will provide systems tied to fire response, evacuation and electrical resilience. For COOs and CFOs, this is a procurement signal as much as a donation.

• Low-voltage switchgear panels will be designed, supplied and tested.
• Fire alarm and voice evacuation systems are included.
• Central battery systems will support emergency power needs.
• Testing, commissioning and factory acceptance processes are part of the scope.

"Landmark projects such as the Hamdan Bin Rashid Cancer Hospital represent an important investment in the future of healthcare in the UAE."
Easa Al Gurg, Group CEO, Al Gurg Group

Capacity signal for oncology operators

Hamdan Bin Rashid Cancer Hospital is scheduled to open in 2026 as part of Dubai Health's academic health system. Dubai Health says the 59,000-square-metre campus at Dubai Healthcare City Phase 2 is planned with 53 clinics, 21 clinical research areas, 60 infusion rooms, 10 urgent care rooms, 5 radiotherapy rooms, 116 inpatient beds and 19 gardens.

The numbers point to an ambulatory oncology model with research built into the operating plan. Private oncology providers should watch the 60 infusion rooms and 5 radiotherapy rooms, because they indicate direct future competition in chemotherapy, radiation oncology, diagnostics and survivorship services once referrals start moving through Dubai Health's network.

Medical directors should also track the 21 clinical research areas. A hospital with that research footprint can become a trial site for oncology drugs, diagnostics and precision-medicine workflows, which may affect referral patterns across Dubai, Abu Dhabi and the Northern Emirates.

Regulatory and procurement implications

In Dubai, providers report to the Dubai Health Authority (DHA). Operators in Abu Dhabi work under the Department of Health Abu Dhabi (DOH), and providers in the Northern Emirates report to the Ministry of Health and Prevention (MOHAP).

For COOs, the near-term issue is commissioning discipline. DHA licensing, civil defence approvals, life-safety certification and biomedical commissioning will converge before the first patient is treated. Any provider expanding oncology capacity in Dubai should benchmark fire alarm, evacuation, emergency power and infusion-suite workflows against the new public-sector flagship.

For vendors, the sales opening is specific. Hamdan Bin Rashid Cancer Hospital will need integrated systems across facilities management, clinical scheduling, infusion operations, radiation oncology, pharmacy, trial enrolment and remote patient support. CIOs selling into oncology groups should expect buyers to ask whether their systems can support Dubai Health referrals, DHA reporting and multi-site continuity of care by 2026.

The number to remember is AED 20 million. The deadline to watch is the 2026 opening, when Hamdan Bin Rashid Cancer Hospital may start changing oncology referral flows, vendor requirements and capacity planning across Dubai.